CURRENT RECRUITING CLINICAL TRIALS
NA-931 (Bioglutide TM): for the treatment of obesity
NA-931TM (Bioglutide TM), a quadruple receptor agonist, has demonstrated a proof of efficacy and safety for potential treatment of obesity. NA-931 regulates the homeostasis of IGF-1, GLP-1, GIP and Glucagon to facilitate weight loss without many of the adverse events associated with current obesity drugs.
NA-931 (Bioglutide TM) has been developed for chronic weight management in adults with a body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
NA-931 (Bioglutide TM) is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments.
"Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition” has been posted on https://clinicaltrials.gov of the National Institute of Health, USA (ClinicalTrials.gov ID NCT06564753)
“Phase 2 on Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese” ClinicalTrials.gov ID NCT06732245
NA-921 (Bionedtide TM): for the treatment of Rett Syndrome
NA-921 (Bionetide)TMis a small molecule drug that is in Phase 3 clinical trials for the treatment of Rett Syndrome.
The Phase 3 clinical protocol "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome" has been posted on https://clinicaltrials.gov of the Nationaal Institute of Health- United States of America. (ClinicalTrials.gov ID NCT06840496)
If you wish to participate as a patient or a care-giver of the patient, please complete the online form: